Taiwan News4h
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for ...
Taiwan News8h
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
The data set from the double-blind phase of the RewinD-LB trial presented today at ILBDC is now accessible in the Investor section of the CervoMed website https://www.cervomed.com/.